We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI Stock Gains Following the ALERT Trial Result Announcement
Read MoreHide Full Article
Key Takeaways
Tempus AI says ALERT trial met endpoint; ECN alerts beat usual care and interventions.
TEM saw alerts drive 40% more valve procedures and 27% more heart team evaluations within 90 days.
TEM trial covered 765 clinicians and 2,016 echos; device-agnostic EHR alerts target undertreatment gaps.
Tempus AI, Inc. (TEM - Free Report) recently presented results from the ALERT (addressing undertreatment and health equity in aortic stenosis and mitral regurgitation using an integrated ehr platform) trial at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study was conducted in collaboration with Medtronic (MDT - Free Report) .
The study demonstrated that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR).
TEM Stock’s Likely Trend Following the News
Since the announcement, TEM shares have surged 4%, closing yesterday’s session at $47.03.
Tempus continues to expand its leadership in precision medicine through a series of impactful research initiatives and clinical validations. Throughout 2025 and early 2026, the company reported several key studies highlighting the power of its AI-driven diagnostics to improve cancer treatment decisions. We expect the news to further boost MDT stock price in the upcoming days.
Tempus has a market capitalization of $8.08 billion at present. The Zacks Consensus Estimate for 2026 earnings per share (EPS) implies growth of 44.3%, outperforming the industry’s 14.7% growth.
Industry Prospects & Significance of ALERT Trial
According to Orion Market Research report, the valvular heart disease market is projected to reach $64.5 billion by 2035, at a CAGR of 11.4% during 2025-2035. Valvular heart disease is a leading cause of morbidity and mortality, though it remains frequently undertreated.
For patients with untreated symptomatic severe AS, mortality approaches 50% within just two years. Similarly, untreated severe MR carries a median survival of only five years. The ALERT trial determines if automated, AI-driven alerts could bridge this critical gap in care delivery. By leveraging the Tempus Next platform, the trial enabled real-time detection of significant disease and automatically delivered site-specific, guideline-based care notifications directly to providers.
Beyond clinical efficiency, a central objective of the ALERT trial was to confront the persistent disparities that leave patients at higher risk of being undertreated. These findings suggest that EHR-integrated clinical decision support can serve as a powerful, scalable, and standardized approach to care delivery, helping ensure that high-risk findings receive timely action regardless of a patient’s demographics or care setting.
About TEM’s ALERT Trial Result
The ALERT trial included 765 clinicians and 2016 echocardiograms across five health systems and 35 hospitals in the United States. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis. This means that patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group.
Image Source: Zacks Investment Research
By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days. These alerts effectively reduced clinical inertia, prompting earlier specialist referrals and ensuring patients received interventions within established benchmarks for timely care.
While the ALERT trial was conducted in collaboration with Medtronic, the automated clinician notifications were designed to be device-agnostic to promote standardized care delivery, without requiring providers to use specific Medtronic devices for recommended evaluations or interventions.
TEM’s Another Development
Tempus recently entered into a strategic collaboration with Daiichi Sankyo to accelerate the clinical development and differentiation of an antibody-drug conjugate (ADC) program in oncology.
TEM Stock Price Performance
Over the past year, TEM stock has surged 1.9%, outperforming the industry’s 23.7% decline.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%.
Globus Medical shares have risen 14% over the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%.
BrightSpring Health Services shares have soared 134.5% over the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Tempus AI Stock Gains Following the ALERT Trial Result Announcement
Key Takeaways
Tempus AI, Inc. (TEM - Free Report) recently presented results from the ALERT (addressing undertreatment and health equity in aortic stenosis and mitral regurgitation using an integrated ehr platform) trial at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study was conducted in collaboration with Medtronic (MDT - Free Report) .
The study demonstrated that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR).
TEM Stock’s Likely Trend Following the News
Since the announcement, TEM shares have surged 4%, closing yesterday’s session at $47.03.
Tempus continues to expand its leadership in precision medicine through a series of impactful research initiatives and clinical validations. Throughout 2025 and early 2026, the company reported several key studies highlighting the power of its AI-driven diagnostics to improve cancer treatment decisions. We expect the news to further boost MDT stock price in the upcoming days.
Tempus has a market capitalization of $8.08 billion at present. The Zacks Consensus Estimate for 2026 earnings per share (EPS) implies growth of 44.3%, outperforming the industry’s 14.7% growth.
Industry Prospects & Significance of ALERT Trial
According to Orion Market Research report, the valvular heart disease market is projected to reach $64.5 billion by 2035, at a CAGR of 11.4% during 2025-2035. Valvular heart disease is a leading cause of morbidity and mortality, though it remains frequently undertreated.
For patients with untreated symptomatic severe AS, mortality approaches 50% within just two years. Similarly, untreated severe MR carries a median survival of only five years. The ALERT trial determines if automated, AI-driven alerts could bridge this critical gap in care delivery. By leveraging the Tempus Next platform, the trial enabled real-time detection of significant disease and automatically delivered site-specific, guideline-based care notifications directly to providers.
Beyond clinical efficiency, a central objective of the ALERT trial was to confront the persistent disparities that leave patients at higher risk of being undertreated. These findings suggest that EHR-integrated clinical decision support can serve as a powerful, scalable, and standardized approach to care delivery, helping ensure that high-risk findings receive timely action regardless of a patient’s demographics or care setting.
About TEM’s ALERT Trial Result
The ALERT trial included 765 clinicians and 2016 echocardiograms across five health systems and 35 hospitals in the United States. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis. This means that patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group.
Image Source: Zacks Investment Research
By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days. These alerts effectively reduced clinical inertia, prompting earlier specialist referrals and ensuring patients received interventions within established benchmarks for timely care.
While the ALERT trial was conducted in collaboration with Medtronic, the automated clinician notifications were designed to be device-agnostic to promote standardized care delivery, without requiring providers to use specific Medtronic devices for recommended evaluations or interventions.
TEM’s Another Development
Tempus recently entered into a strategic collaboration with Daiichi Sankyo to accelerate the clinical development and differentiation of an antibody-drug conjugate (ADC) program in oncology.
TEM Stock Price Performance
Over the past year, TEM stock has surged 1.9%, outperforming the industry’s 23.7% decline.
TEM’s Zacks Rank and Top Picks
Tempus currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Envista (NVST - Free Report) , Globus Medical (GMED - Free Report) and BrightSpring Health Services (BTSG - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%.
Globus Medical shares have risen 14% over the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%.
BrightSpring Health Services shares have soared 134.5% over the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%.